Arcus Biosciences, Inc. (NYSE:RCUS) President Juan C. Jaen Sells 3,900 Shares

Arcus Biosciences, Inc. (NYSE:RCUSGet Free Report) President Juan C. Jaen sold 3,900 shares of the business’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $20.06, for a total transaction of $78,234.00. Following the completion of the transaction, the president now owns 1,211,365 shares of the company’s stock, valued at approximately $24,299,981.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Arcus Biosciences Stock Down 5.1 %

RCUS traded down $1.03 on Wednesday, reaching $19.15. The company had a trading volume of 749,181 shares, compared to its average volume of 936,060. The stock has a 50-day moving average price of $17.14 and a 200-day moving average price of $17.28. Arcus Biosciences, Inc. has a 1 year low of $12.95 and a 1 year high of $25.47. The stock has a market capitalization of $1.74 billion, a PE ratio of -4.61 and a beta of 0.78.

Arcus Biosciences (NYSE:RCUSGet Free Report) last announced its earnings results on Wednesday, February 21st. The company reported ($1.08) EPS for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.01. Arcus Biosciences had a negative net margin of 262.39% and a negative return on equity of 57.17%. The business had revenue of $31.00 million during the quarter, compared to analysts’ expectations of $28.30 million. During the same period in the prior year, the company earned ($0.93) earnings per share. The business’s revenue was down 8.8% compared to the same quarter last year. As a group, analysts expect that Arcus Biosciences, Inc. will post -3.16 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Arcus Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the business. BluePath Capital Management LLC purchased a new stake in shares of Arcus Biosciences in the third quarter valued at about $28,000. GAMMA Investing LLC acquired a new position in shares of Arcus Biosciences during the fourth quarter worth about $31,000. Osaic Holdings Inc. increased its stake in shares of Arcus Biosciences by 51.4% during the second quarter. Osaic Holdings Inc. now owns 1,620 shares of the company’s stock worth $34,000 after acquiring an additional 550 shares during the period. Public Employees Retirement System of Ohio acquired a new position in shares of Arcus Biosciences during the third quarter worth about $36,000. Finally, Strs Ohio acquired a new position in shares of Arcus Biosciences during the third quarter worth about $43,000. 74.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on RCUS shares. Wedbush restated an “outperform” rating and issued a $30.00 price target on shares of Arcus Biosciences in a research note on Thursday, February 22nd. Morgan Stanley lowered their target price on shares of Arcus Biosciences from $38.00 to $35.00 and set an “overweight” rating for the company in a research note on Monday, November 13th. Cantor Fitzgerald lowered their target price on shares of Arcus Biosciences from $46.00 to $36.00 and set an “overweight” rating for the company in a research note on Wednesday, November 8th. Finally, Mizuho lowered their target price on shares of Arcus Biosciences from $51.00 to $42.00 and set a “buy” rating for the company in a research note on Tuesday, January 30th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Arcus Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $41.25.

View Our Latest Report on Arcus Biosciences

About Arcus Biosciences

(Get Free Report)

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT investigational monoclonal antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.

Recommended Stories

Insider Buying and Selling by Quarter for Arcus Biosciences (NYSE:RCUS)

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.